Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion

Pietro Turco, Antonio De Simone, Vincenzo La Rocca, Bilal El Jamal, Pasquale Nocerino, Costantino Astarita, Carmine De Matteis, Vincenzo Messina, Luciano Greco, Raffaele Rotunno, Tommaso Di Napoli, Dino Franco Vitale, Giuseppe Stabile

Research output: Contribution to journalArticle

Abstract

The flecainide infusion test has been proposed to screen candidates for hybrid pharmacological and ablation therapy. We report the long-term follow-up of 154 consecutive patients with paroxysmal or persistent atrial fibrillation (AF) who developed atrial flutter (AFL) during flecainide infusion (IC AFL), treated with inferior vena cava-tricuspid annulus isthmus catheter ablation and oral flecainide (hybrid therapy). Over a mean of 54.1 ± 13.1 months 82 patients (53%) remained free of AF and AFL. Flecainide was discontinued because of adverse effects in 6 patients (4%). A history of persistent AF, and the documentation of ≥1 spontaneous AFL episode before the flecainide test were independent predictors of successful hybrid therapy. In patients with paroxysmal AF without documented spontaneous AFL, the long-term efficacy of hybrid therapy was 38.5% (P = 0.03). The flecainide infusion test reliably detects candidates for hybrid therapy. The efficacy of this therapy is maintained over the long-term with a high patient compliance.

Original languageEnglish
JournalPACE - Pacing and Clinical Electrophysiology
Volume28
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Jan 2005

Fingerprint

Flecainide
Atrial Flutter
Atrial Fibrillation
Therapeutics
Catheter Ablation
Inferior Vena Cava
Patient Compliance
Documentation
Pharmacology

Keywords

  • Ablation
  • Atrial flutter
  • Fibrillation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion. / Turco, Pietro; De Simone, Antonio; La Rocca, Vincenzo; El Jamal, Bilal; Nocerino, Pasquale; Astarita, Costantino; De Matteis, Carmine; Messina, Vincenzo; Greco, Luciano; Rotunno, Raffaele; Di Napoli, Tommaso; Vitale, Dino Franco; Stabile, Giuseppe.

In: PACE - Pacing and Clinical Electrophysiology, Vol. 28, No. SUPPL. 1, 01.2005.

Research output: Contribution to journalArticle

Turco, P, De Simone, A, La Rocca, V, El Jamal, B, Nocerino, P, Astarita, C, De Matteis, C, Messina, V, Greco, L, Rotunno, R, Di Napoli, T, Vitale, DF & Stabile, G 2005, 'Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion', PACE - Pacing and Clinical Electrophysiology, vol. 28, no. SUPPL. 1. https://doi.org/10.1111/j.1540-8159.2005.00032.x
Turco, Pietro ; De Simone, Antonio ; La Rocca, Vincenzo ; El Jamal, Bilal ; Nocerino, Pasquale ; Astarita, Costantino ; De Matteis, Carmine ; Messina, Vincenzo ; Greco, Luciano ; Rotunno, Raffaele ; Di Napoli, Tommaso ; Vitale, Dino Franco ; Stabile, Giuseppe. / Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion. In: PACE - Pacing and Clinical Electrophysiology. 2005 ; Vol. 28, No. SUPPL. 1.
@article{cc92ab6e10d24687a10479c8519a604c,
title = "Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion",
abstract = "The flecainide infusion test has been proposed to screen candidates for hybrid pharmacological and ablation therapy. We report the long-term follow-up of 154 consecutive patients with paroxysmal or persistent atrial fibrillation (AF) who developed atrial flutter (AFL) during flecainide infusion (IC AFL), treated with inferior vena cava-tricuspid annulus isthmus catheter ablation and oral flecainide (hybrid therapy). Over a mean of 54.1 ± 13.1 months 82 patients (53{\%}) remained free of AF and AFL. Flecainide was discontinued because of adverse effects in 6 patients (4{\%}). A history of persistent AF, and the documentation of ≥1 spontaneous AFL episode before the flecainide test were independent predictors of successful hybrid therapy. In patients with paroxysmal AF without documented spontaneous AFL, the long-term efficacy of hybrid therapy was 38.5{\%} (P = 0.03). The flecainide infusion test reliably detects candidates for hybrid therapy. The efficacy of this therapy is maintained over the long-term with a high patient compliance.",
keywords = "Ablation, Atrial flutter, Fibrillation",
author = "Pietro Turco and {De Simone}, Antonio and {La Rocca}, Vincenzo and {El Jamal}, Bilal and Pasquale Nocerino and Costantino Astarita and {De Matteis}, Carmine and Vincenzo Messina and Luciano Greco and Raffaele Rotunno and {Di Napoli}, Tommaso and Vitale, {Dino Franco} and Giuseppe Stabile",
year = "2005",
month = "1",
doi = "10.1111/j.1540-8159.2005.00032.x",
language = "English",
volume = "28",
journal = "PACE - Pacing and Clinical Electrophysiology",
issn = "0147-8389",
publisher = "Wiley-Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion

AU - Turco, Pietro

AU - De Simone, Antonio

AU - La Rocca, Vincenzo

AU - El Jamal, Bilal

AU - Nocerino, Pasquale

AU - Astarita, Costantino

AU - De Matteis, Carmine

AU - Messina, Vincenzo

AU - Greco, Luciano

AU - Rotunno, Raffaele

AU - Di Napoli, Tommaso

AU - Vitale, Dino Franco

AU - Stabile, Giuseppe

PY - 2005/1

Y1 - 2005/1

N2 - The flecainide infusion test has been proposed to screen candidates for hybrid pharmacological and ablation therapy. We report the long-term follow-up of 154 consecutive patients with paroxysmal or persistent atrial fibrillation (AF) who developed atrial flutter (AFL) during flecainide infusion (IC AFL), treated with inferior vena cava-tricuspid annulus isthmus catheter ablation and oral flecainide (hybrid therapy). Over a mean of 54.1 ± 13.1 months 82 patients (53%) remained free of AF and AFL. Flecainide was discontinued because of adverse effects in 6 patients (4%). A history of persistent AF, and the documentation of ≥1 spontaneous AFL episode before the flecainide test were independent predictors of successful hybrid therapy. In patients with paroxysmal AF without documented spontaneous AFL, the long-term efficacy of hybrid therapy was 38.5% (P = 0.03). The flecainide infusion test reliably detects candidates for hybrid therapy. The efficacy of this therapy is maintained over the long-term with a high patient compliance.

AB - The flecainide infusion test has been proposed to screen candidates for hybrid pharmacological and ablation therapy. We report the long-term follow-up of 154 consecutive patients with paroxysmal or persistent atrial fibrillation (AF) who developed atrial flutter (AFL) during flecainide infusion (IC AFL), treated with inferior vena cava-tricuspid annulus isthmus catheter ablation and oral flecainide (hybrid therapy). Over a mean of 54.1 ± 13.1 months 82 patients (53%) remained free of AF and AFL. Flecainide was discontinued because of adverse effects in 6 patients (4%). A history of persistent AF, and the documentation of ≥1 spontaneous AFL episode before the flecainide test were independent predictors of successful hybrid therapy. In patients with paroxysmal AF without documented spontaneous AFL, the long-term efficacy of hybrid therapy was 38.5% (P = 0.03). The flecainide infusion test reliably detects candidates for hybrid therapy. The efficacy of this therapy is maintained over the long-term with a high patient compliance.

KW - Ablation

KW - Atrial flutter

KW - Fibrillation

UR - http://www.scopus.com/inward/record.url?scp=19944430782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944430782&partnerID=8YFLogxK

U2 - 10.1111/j.1540-8159.2005.00032.x

DO - 10.1111/j.1540-8159.2005.00032.x

M3 - Article

C2 - 15683478

AN - SCOPUS:19944430782

VL - 28

JO - PACE - Pacing and Clinical Electrophysiology

JF - PACE - Pacing and Clinical Electrophysiology

SN - 0147-8389

IS - SUPPL. 1

ER -